Goodman Capital
VC Fund
Singapore, Singapore
Goodman Capital is a VC fund in Singapore focused on Biotechnology and Medical. Private investment firm investing in technology and biotech companies across USA and Asia from early-stage to pre-IPO
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Goodman Capital invests in
Stages Goodman Capital invests in
Countries Goodman Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$10M
- Series A
- $43M–$53M
Investment Focus
Industry
- Biotechnology 3 (43%)
- Medical 2 (29%)
- Health Care 2 (29%)
- Therapeutics 2 (29%)
- Hotel 1 (14%)
Stage
- Series A 3 (43%)
- Seed 2 (29%)
- Angel 1 (14%)
Country
- Singapore 2 (29%)
- United States 2 (29%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jeffrey Lu
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | $43M / Series A / May 26, 2021 | ||
| Senti Biosciences is a developer of a programmable biology platform for cancer therapies. Its therapeutics specialize in cell engineering and biological programming to build the future of gene and cell-based therapies that enable physicians to give patients life-saving treatments at an affordable cost. | $53M / Series A / Feb 27, 2018 | ||
| Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | $10M / Seed / Jan 31, 2018 | ||
| ZUZU Hospitality is chain for independent hotels, delivering revenue growth through distribution and revenue management.As such, we are the indisputable primary partner to hoteliers in driving revenue. Acting as their hotel operating system, we power their back office revenue generation business operations, allowing them to focus on being greathoteliers. | $2M / Seed / Oct 23, 2017 | ||
| Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases.The company is developing innovative, safe and highly effective therapeutics that address today's biggest healthcare challenges, enabling customers to access first-in-class antibody therapeutics for the treatment of fibrotic human diseases. | Series A / Apr 04, 2017 | ||
| ZUZU Hospitality is chain for independent hotels, delivering revenue growth through distribution and revenue management.As such, we are the indisputable primary partner to hoteliers in driving revenue. Acting as their hotel operating system, we power their back office revenue generation business operations, allowing them to focus on being greathoteliers. | Angel / May 01, 2016 | ||
| ZUZU Hospitality is chain for independent hotels, delivering revenue growth through distribution and revenue management.As such, we are the indisputable primary partner to hoteliers in driving revenue. Acting as their hotel operating system, we power their back office revenue generation business operations, allowing them to focus on being greathoteliers. | $1M / Seed / May 01, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Goodman Capital invest in?
Goodman Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Goodman Capital's check size?
Goodman Capital typically joins rounds of $1M–$10M at Seed and $43M–$53M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Goodman Capital participates in.
How do I contact Goodman Capital?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Goodman Capital?
The team at Goodman Capital includes Jeffrey Lu (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
